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 The aim of this study was to estimate the
proportion of strokes occurring among hypertensive pa-
tients in The Netherlands attributable to under-treatment
of hypertension.
METHODS: The baseline data reported in this study
were collected in two population-based studies. Approxi-
mately 45,000 men and women aged 20 years and over
were examined in these studies. In all participants, blood
pressure, serum lipid levels, weight, and height were mea-
sured, and all respondents completed a questionnaire on
cardiovascular risk factors and current use of medication.
For the classification of under-treatment, the Dutch
guidelines for management of hypertension were used
(pharmacological treatment when diastolic blood pres-
sure [DBP] is between 100 and 105 mmHg and one or
more cardiovascular risk factors are present, or when the
systolic blood pressure [SBP] is between 160 and 180
mmHg and one or more cardiovascular risk factors are
present, or when DBP  105 mmHg, or when SBP  180
mmHg; treatment goal is a DBP  90 mmHg and a SBP 
160 mmHg). Information on fatal and non-fatal strokes
during follow-up were obtained through patient records
from general practitioners.
RESULTS: Of the subjects, 3168 were hypertensive. Sub-
jects who were not in need of pharmacological treatment
according to the guidelines and subjects with missing
data were excluded. Follow-up was complete for 2369
(91%) of the 2616 remaining subjects. Mean duration of
follow-up was 4.6 years. Compared to treated and con-
trolled hypertension, the adjusted relative risks of stroke
were 1.30 [95% CI 0.70–2.44] and 1.76 [95% CI 1.05–
2.94] for treated and uncontrolled hypertension, and un-
treated hypertension that should be treated, respectively.
Among hypertensives the proportion of strokes attribut-
able to under-treatment of hypertension was about 28%.
CONCLUSION: Improvement of control of hyperten-
sion among treated hypertensives, detection of hyperten-
sion, and adherence to the current guidelines on the man-
agement of hypertension might prevent a considerable
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Presbyterian-St. Luke’s Medical Center, Chicago, IL, USA
The long-term prognostic influence of left ventricular sys-
tolic function (LVERSUSF) in diagnosing patients with con-
gestive heart failure (CHF) has been widely documented.
However, the short-term prognostic significance of
LVERSUSF on early hospital readmission for CHF is lim-
ited.
OBJECTIVES: The study purpose was to examine the in-
fluence of LVERSUSF on 90-day readmission for CHF.
METHODS: Medical records were reviewed for all pa-
tients with a principle diagnosis of CHF discharged alive
from January 1 through June 30, 1997 at an urban public
hospital. LVERSUSF assessments within 6 months prior to
discharge were used to classify patients as normal LVER-
SUSF or left-ventricular (LV) systolic dysfunction.
RESULTS: Among 387 patients, 303 (78.3%) had
6-month assessments of LVERSUSF. Among patients
with LVERSUSF assessments, 207 patients (68.3%) had
LV systolic dysfunction and 96 patients (31.7%) had
normal LV systolic function. A total of 54 (26.1%) of the
207 patients with LV systolic dysfunction were readmit-
ted for CHF within 90 days, versus 13 (13.5%) of the 96
patients with normal LVERSUSF that were readmitted
(p  0.01). Multivariate logistic regression analysis (in-
cluding: age, gender, prior history of CHF, comorbidities,
NYHA class, medication adherence) showed 90-day read-
mission for CHF was more likely in patients with LV sys-
tolic dysfunction than in those with normal LVERSUSF af-
ter adjusting for other identified risk factors (p  0.05).
CONCLUSIONS: LV systolic dysfunction appears to in-
crease the likelihood of 90-day readmission among pa-
tients with CHF. The findings underscore the ability of
LVERSUSF to stratify patients hospitalized for CHF and
suggest potential usefulness in aiding management by
identifying higher risk patients.
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 To determine inpatient resource use, cost,
and major cost drivers for idiopathic Parkinson’s disease
(PD).
METHODS: A retrospective study, evaluating patients ad-
mitted at a large academic medical center between July
1994 and June 1997 with a primary or secondary diagnosis
of PD. Average length of stay (ALOS), resource use, institu-
tional cost (including overhead), demographics, and admis-
sion severity information was extracted from the inpatient
cost accounting system. Resources and costs were then
grouped into categories based on type of service provided.
RESULTS: Sixteen patients with primary diagnosis
(PDX) and 378 patients with secondary diagnosis (SDX)
of PD were identified. Of the 378 SDX patients, only 54
patients were assumed to have a PD-related primary di-
agnosis and were included in the analysis. Although the





SDX group, their average costs per hospitalization were
less ($8,145 versus $18,617) in part due to shorter ALOS
(7.9 versus 14.3 days). Costs due to rehabilitation (8%
versus 3%) and other services including surgical care and
cast room (20% versus 5%) were higher in the SDX
group, presumably due to 85% of these patients receiving
acute rehabilitation, fractures, or falls related diagnoses.
For both groups, nursing care was the major cost driver
(73% and 58%). Services including radiology, labora-
tory, pharmacy, EKG, EEG, and EMG totaled 19% and
14% of the PDX and SDX group costs, respectively.
CONCLUSION: The study found that most patients
were admitted for the treatment of Parkinson’s disease–
related (secondary) diagnoses rather than for primary di-
agnosis of Parkinson’s disease. Providing better care at
home and applying appropriate safety precautions may
potentially impact a portion of these admissions and re-




POTENTIAL SAVINGS IN THE COST OF 


































Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVE: We estimated savings in the cost of caring
for Alzheimer’s disease patients during 6 months, 1 year,
and 2 years treatment with rivastigmine. An intermediate
objective was to estimate the relationship between dis-
ease progression and institutionalization.
METHODS: We assessed the relationship between Mini-
Mental State Examination (MMSE) score and institutional-
ization using a piecewise Cox proportional hazard model.
To estimate cost savings from treatments lasting 6 months,
1 year, and 2 years, estimates of the probability of institu-
tionalization were integrated with data from a 6-month,
Phase III clinical trial of rivastigmine and a hazard model
of disease progression.
RESULTS: Our data suggest that savings in the overall
cost of caring for patients with mild and moderate AD
can be as high as $4839.00 per patient after 2 years treat-
ment. Further, the probability of institutionalization in-
creases steadily as MMSE score falls. Among our study
subjects age, race, level of education, and marital status
were significant predictors of institutionalization, while
gender had little effect.
CONCLUSION: Using rivastigmine in treating Alzhe-
imer’s disease results in a delay in disease progression for
patients who begin treatment during the mild or moder-
ate stages of the disease. By delaying the probability that
a patient will be institutionalized, the cost of caring for


































Division of Medical Assistance, Boston, MA, USA
OBJECTIVE: We developed and then validated a self-
administered health-related quality of life survey for indi-
viduals with schizophrenia living in the community as
part of the Schizophrenia Outcomes Assessment Project
(SOAP).
METHODS: Fifteen hundred adult consumers with schizo-
phrenia (61% male) were recruited from five states (AZ,
MA, SC, WA, WI). Consumers completed four adminis-
trations of a 51-item survey assessment in 3 months. A
staff version of consumer status was also completed at
each administration.
RESULTS: Factor analysis, based on 1382 consumers
who answered all 51 items, supports eight factors: satis-
faction, self-concept, work/role, mental health, interper-
sonal, medication effects, activities of daily living, and
physical function. The combined score of the instrument
ranges from a low of 51 to a high of 204 with a popula-
tion mean of 150.6  20.2. Cronbach alpha of the
51-item survey is 0.9242 with all but one of the eight fac-
tors being over 0.700 (medication effects was 0.624).
Each item had a stronger correlation with its factor score
with that item removed than with other factors. Face and
content validity were established by an expert panel and
consumers. Convergent validity was established by com-
paring consumers’ global assessment of their status for
each factor to the companion actual factor scores; con-
gruence was significant (p  0.0001). Divergent validity
was established by comparing staffs’ placement of the
consumers into four levels of functionality for each of the
eight factors. Except for the medication effects factor, the
association between staff assessment and consumer fac-
tor scores was significant (p  0.0001).
CONCLUSION: The SOAP-51 is a valid and reliable
health-related quality of life instrument for use in a popu-





ASSESSING UTILITIES FOR DEPRESSION 
OUTCOMES: PREFERENCES OF DEPRESSED 
PATIENTS AND THE GENERAL PUBLIC
Gonzales J, Bowers B, Weinfurt K, Bajwa K, Harvey J, 
Schulman K
Clinical Economics Research Unit, Departments of Psychiatry 
and Medicine, Georgetown University Medical Center, 
Washington, DC, USA
Depression is a public health problem with a lifetime preva-
lence estimate over 17% and the second leading cause
of disease burden worldwide. Despite the existence of
